Core Viewpoint - The stock of Aosaikang has shown a significant increase of 51.47% year-to-date, with recent trading activity indicating a mixed performance in the short term [1][2]. Group 1: Stock Performance - As of November 12, Aosaikang's stock price rose by 2.03% to 19.07 CNY per share, with a trading volume of 57.05 million CNY and a turnover rate of 0.33%, resulting in a total market capitalization of 17.7 billion CNY [1]. - Year-to-date, Aosaikang's stock has increased by 51.47%, with a slight rise of 0.10% over the last five trading days, a decline of 1.60% over the last 20 days, and a significant drop of 27.02% over the last 60 days [1]. - The company has appeared on the "龙虎榜" (a list of stocks with significant trading activity) twice this year, with the most recent occurrence on July 16 [1]. Group 2: Financial Performance - For the period from January to September 2025, Aosaikang reported a revenue of 1.434 billion CNY, reflecting a year-on-year growth of 3.57%, while the net profit attributable to shareholders increased by 75.81% to 223 million CNY [2]. - Since its A-share listing, Aosaikang has distributed a total of 721 million CNY in dividends, with 111 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of October 20, Aosaikang had 27,500 shareholders, an increase of 1.09% from the previous period, with an average of 33,706 circulating shares per shareholder, a decrease of 1.08% [2]. - Among the top ten circulating shareholders, notable changes include an increase in holdings by Yongying Medical Innovation Mixed Fund and the entry of new shareholders such as Yongying Ruixin Mixed Fund and Yongying Stable Enhanced Bond Fund [3].

Core Points - Jiangsu Su Yang Investment Co., Ltd. has reduced its shareholding in Aosaikang (002755.SZ) by 9,281,600 shares, representing 1.00% of the company's total share capital [1] - Prior to this reduction, Su Yang Investment held 119,782,160 shares, which accounted for 12.91% of the total share capital [1] - After the reduction, Su Yang Investment now holds 110,500,560 shares, which is 11.91% of the total share capital [1]

格隆汇11月11日丨奥赛康(002755.SZ)公布，近日收到公司股东江苏苏洋投资实业有限公司（简称"苏洋 投资"）出具的《股份变动告知函》，苏洋投资自2025年9月15日至2025年11月10日期间累计减持本公司 股份9,281,600股，占本公司总股本的1.00%。本次股份变动前，苏洋投资持有本公司股份119,782,160 股，占本公司总股本的12.91%；本次股份变动后，苏洋投资持有本公司股份110,500,560股，占本公司 总股本的11.91%。 ...

注：公告中若出现合计数与各分项数值相加之和在尾数上存在差异，系因持股比 例数据按照四舍五入保留两位小数所致。 二、备查文件 持股 5%以上股东股份变动触及 1%的公告 持股 5%以上的股东江苏苏洋投资实业有限公司保证向本公司提 供的信息内容真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供 的信息一致。 北京奥赛康药业股份有限公司（以下简称"公司"）于近日收到公司股东江苏 苏洋投资实业有限公司（以下简称"苏洋投资"）出具的《股份变动告知函》，苏 洋投资自 2025 年 9 月 15 日至 2025 年 11 月 10 日期间累计减持本公司股份 9,281,600 股，占本公司总股本的 1.00%。本次股份变动前，苏洋投资持有本公司 股份 119,782,160 股，占本公司总股本的 12.91%；本次股份变动后，苏洋投资持 有本公司股份 110,500,560 股，占本公司总股本的 11.91%。现将有关情况公告如 下： 1．基本情况 信息披露义务人 江苏苏洋投资实业有限公司 住所 南京市江宁区秣陵街道科学园龙眠大道 618 号 权益变动时间 20 ...

| 交易日期 | 证券代码 | 证券简称 | 成交价格 | 成交量 | 成交金额 | 买方营业部 | 卖方营业部 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | | (元) | (万股/万份) | (万元) | | | | 2025-11-10 | 002755 | 奥赛康 | 16.68 | 17.00 | 283.56 | 招商证券股份有限 | 华泰证券股份有限 | | | | | | | | 公司西安北大街证 | 公司南京分公司 | | | | | | | | 券营业部 | | | 2025-11-10 | 002755 | 奥赛康 | 16.68 | 25.00 | 417.00 | 招商证券股份有限 | 华泰证券股份有限 | | | | | | | | 公司西安北大街证 | 公司南京分公司 | | | | | | | | 券营业部 | | | 2025-11-10 | 002755 | 奥赛康 | 16.68 | 14.00 | 233.52 | 机构专用 | 华泰证券股份有限 | | | | | | | | | 公司南京分公司 | ...

Group 1 - On November 5, Aosaikang executed a block trade of 1 million shares, with a transaction value of 17.2 million yuan, accounting for 5.36% of the total trading volume for the day [1] - The transaction price was 17.2 yuan, representing a discount of 9.71% compared to the market closing price of 19.05 yuan [1]

Core Insights - On November 3, 2025, Aosaikang conducted a block trade of 2.6934 million shares, with a transaction value of 47.1884 million yuan, accounting for 10.96% of the total trading volume for the day. The transaction price was 17.52 yuan, representing a discount of 10.61% compared to the market closing price of 19.6 yuan [1]. Trading Details - The block trade involved multiple transactions at a price of 17.52 yuan per share, with varying volumes and amounts, including: - 11.50 million shares for a total of 201.48 million yuan [2] - 24.00 million shares for a total of 420.48 million yuan [2] - 16.00 million shares for a total of 280.32 million yuan [2] - 22.00 million shares for a total of 385.44 million yuan [2] - 35.00 million shares for a total of 613.20 million yuan [2] - The trades were primarily executed by institutional buyers, with Huatai Securities being a notable seller [2].

Core Insights - As of October 31, a total of 129 stocks in the Shanghai and Shenzhen markets have experienced net financing inflows for five consecutive days or more [1] - The stock with the longest consecutive net inflow is CITIC Bo, which has seen net buying for 14 trading days [1] - Other notable stocks with significant consecutive net inflows include Daimai Co., Weichuang Electric, Foster, Zhenhua Technology, Honghua Digital, Aosaikang, Dongcheng Pharmaceutical, and Huace Navigation [1]

Group 1 - The core viewpoint of the news is that Aosaikang's stock price increased by 5.12%, reaching 19.09 CNY per share, with a total market capitalization of 17.719 billion CNY [1] - Aosaikang Pharmaceutical Co., Ltd. is located in Jiangning Science Park, Nanjing, and was established on December 24, 1996, with its listing date on May 15, 2015 [1] - The company's main business involves the research, production, and sales of drugs, with revenue composition as follows: oncology drugs 38.28%, anti-infection drugs 24.74%, chronic disease drugs 21.65%, digestive drugs 12.33%, and others 2.34% [1] Group 2 - From the perspective of fund holdings, Penghua Fund has one fund heavily invested in Aosaikang, specifically the Penghua Health and Environmental Mixed Fund, which reduced its holdings by 39,100 shares in the third quarter [2] - The current number of shares held by the fund is 283,700, accounting for 4.89% of the fund's net value, making it the third-largest holding [2] - The fund has achieved a year-to-date return of 32.38% and a one-year return of 27.59%, with a total fund size of 120 million CNY [2]

Core Insights - Osai Kang (002755.SZ) reported its Q3 2025 results, revealing that 21 institutional investors hold a total of 747 million shares, accounting for 80.45% of the company's total equity [1] - The top ten institutional investors collectively hold 80.04% of the shares, with a slight decrease of 0.39 percentage points compared to the previous quarter [1] Institutional Holdings - In the public fund sector, six funds increased their holdings, including Yongying Medical Innovation Mixed Fund A and Huaxia Smart Selection Mixed Fund A, with an increase rate of 1.22% [2] - Three public funds reduced their holdings, including Guolian Medical Consumption Mixed Fund A, with a slight decrease in holding percentage [2] - Six new public funds were disclosed this period, including Yongying Ruixin Mixed Fund A and Huaxia Dingrong Bond Fund A [2] - A total of 194 public funds were not disclosed this period, including Penghua Medical Technology Stock A and Southern CSI 1000 ETF [2] Foreign Investment - One foreign fund, Hong Kong Central Clearing Limited, increased its holdings by 0.31% [2] - One foreign fund, Zhongyi Weiye Holdings Limited, reduced its holdings by 0.21% [2]